All articles by GlobalData Healthcare

  1. AACR 2018: revisiting murine models to develop drug combos for KRAS-driven cancers

    Treatment of KRAS-driven cancers is among one of the highest unmet needs in the oncology space. Mutations in KRAS are…
    Read More…

    19 Apr
  2. AACR 2018: SLFN11 predicts response to PARP inhibition in small cell lung cancer

    The recent update on the Phase II TRINITY clinical trial (NCT02674568) of AbbVie’s rovalpituzumab tesirine (Rova-T), an antibody-drug conjugate targeting…
    Read More…

    19 Apr
  3. TaiwanJ’s JKB-121 falls victim to unexpected placebo response in NASH patients

    The future of TaiwanJ Pharmaceuticals’ JKB-121 as a NASH treatment is in jeopardy after it failed to demonstrate efficacy in…
    Read More…

    19 Apr
  4. ILC 2018: NGM’s intravenous NASH therapy shows rapid reduction in liver fat content and fibrosis

    Phase II efficacy data for NGM Biopharmaceuticals’ developmental non-alcoholic steatohepatitis (NASH) drug, NGM-282, was presented at the 2018 International Liver…
    Read More…

    19 Apr
  5. CD40 agonist developments could support Anti-PD-(L)1 therapy in pancreatic cancer

    A major theme of this year’s AACR meeting examines the approaches that aim to further improve the anti-tumour efficacy of…
    Read More…

    18 Apr
  6. ILC 2018: Madrigal Therapeutics’ MCL-3196 reduces liver fat in NASH patients

    Clinical efficacy data for Madrigal Therapeutics’ Phase II NASH therapeutic, MCL-3196, which was presented at the 2018 International Liver Congress…
    Read More…

    17 Apr
  7. ILC 2018: Allergan’s cenicriviroc shows continued fibrosis response in NASH patients in two year extended study

    Evidence that Allergan’s Phase III drug candidate, cenicriviroc, may benefit non-alcoholic steatohepatitis (NASH) patients was presented at the 2018 International…
    Read More…

    17 Apr
  8. Vaccine development: the need for speed

    When responding to outbreaks of viral disease, public health officials are often challenged to reconcile the rapid and unpredictable nature…
    Read More…

    6 Apr
  9. Oral pill to treat psoriasis: could this be a game-changer?

    Dutch company Escalier Biosciences has raised funds of $19M to develop psoriasis treatments. The funding will be utilised to develop…
    Read More…

    3 Apr
  10. Could GLP-1 receptor agonists play a larger role in binge eating disorder treatment?

    Earlier this month, Novo Nordisk published results from a Phase II trial involving 957 participants demonstrating the weight-loss efficacy of…
    Read More…

    3 Apr